Torrent Pharmaceuticals Limited
TORNTPHARM
Rang in Aktien
#1197
Torrent Pharmaceuticals Limited operates as a global pharmaceutical entity,... Torrent Pharmaceuticals Limited operates as a global pharmaceutical entity, managing the entire process from the discovery and development of generic drug formulations to their production and distribution. Its commercial activities extend across key markets such as India, the United States, Germany, and Brazil, alongside various other international territories. The company boasts a broad product catalog, offering treatments for a wide array of medical conditions. This includes therapies for cardiovascular diseases, central nervous system disorders, gastrointestinal issues, women's health concerns, diabetes, pain management, gynecological ailments, oncology, and anti-infective medications. Additionally, Torrent Pharma supplies essential vitamins, minerals, and other nutritional supplements. Beyond its proprietary offerings, the firm also provides contract manufacturing services to other companies. During the COVID-19 pandemic, it demonstrated its commitment by securing licensing agreements for crucial treatments like Baricitinib, Molnupiravir, and Paxlovid. Established in 1959, the company originally operated under the name Trinity Laboratories before officially becoming Torrent Pharmaceuticals Limited in 1971. Its corporate headquarters are located in Ahmedabad, India. Ultimately, Torrent Pharmaceuticals Limited functions as a subsidiary of Torrent Investments Private Limited.
Aktienkurs
$50.31
Zuletzt synchronisiert: 2026-10-19
Marktkapitalisierung
$19.14B
Veränderung (1 Tag)
-0.14%
Veränderung (1 Jahr)
23.83%
Land
IN
Handel Torrent Pharmaceuticals Limited (TORNTPHARM)
Kategorie
Healthcare
Gewinn für Torrent Pharmaceuticals Limited (TORNTPHARM)
Gewinn im Jun 2026 TTM: $316.40M
Laut den aktuellen Finanzberichten von Torrent Pharmaceuticals Limited betragen die aktuellen Gewinne des Unternehmens $316.40M. Im Jahr 2024 erzielte das Unternehmen einen Gewinn von $282.08M, eine Steigerung gegenüber dem Gewinn im Jahr 2023, der $224.77M betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von Torrent Pharmaceuticals Limited von 2005 bis 2026
Gewinn am Ende jedes Jahres
| Jahr | Gewinn | ändert |
|---|---|---|
| 2026 (TTM) | $316.40M | 1.24% |
| 2025 | $312.51M | 10.79% |
| 2024 | $282.08M | 25.50% |
| 2023 | $224.77M | 39.18% |
| 2022 | $161.50M | -22.54% |
| 2021 | $208.49M | 32.37% |
| 2020 | $157.51M | 94.73% |
| 2019 | $80.88M | -43.43% |
| 2018 | $142.99M | -14.78% |
| 2017 | $167.79M | -52.57% |
| 2016 | $353.73M | 134.86% |
| 2015 | $150.61M | -3.94% |
| 2014 | $156.79M | 46.48% |
| 2013 | $107.04M | 51.35% |
| 2012 | $70.72M | -8.03% |
| 2011 | $76.89M | -0.54% |
| 2010 | $77.31M | 104.22% |
| 2009 | $37.86M | 1.60% |
| 2008 | $37.26M | 48.13% |
| 2007 | $25.15M | 44.18% |
| 2006 | $17.45M | 33.96% |
| 2005 | $13.02M | 0.00% |
Gewinn ähnlicher Unternehmen oder Konkurrenten
| Unternehmen | Gewinn | Gewinnunterschied | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 457.70% |
IN
|
